Reports - Non-Invasive Blood Glucose Monitoring Systems Market
Non-Invasive Blood Glucose Monitoring Systems Market Valuation and Growth Forecast 2025-2035 by Technology (Spectroscopy, Electromagnetic, Microwave, Ultrasonic, Thermal, Others) by End Users (Hospitals, Homecare, Clinics) by Modality (Wearable, Non-wearable) by Distribution Channel (Retail Sales, Institutional Sales) by Region (North America, Europe, Asia Pacific, Latin America, Middle East & Africa
Industry Leaders Trust Us For Actionable Intelligence
USD 33.9 Million
USD 284.43 Million
21.3%
North America
Europe
2024
2021 - 2023
2025 - 2035
By Technology, By End Users, By Modality, By Distribution Channel, By Region
The final deliverable will encompass both quantitative and qualitative data, providing a comprehensive analysis of the market. The scope is customizable.
The global Non-Invasive Blood Glucose Monitoring Systems Market is valued at USD 33.9 Million in 2024 and is projected to reach a value of USD 284.43 Million by 2035 at a CAGR (Compound Annual Growth Rate) of 21.3% between 2025 and 2035. The market is driven by increasing demand for user-friendly and painless monitoring solutions, as well as AI integration for personalized diabetes management.
The Technology Segment is divided into Spectroscopy, Electromagnetic, microwave, ultrasonic, thermal, and Others. The Spectroscopy held the dominant share in 2024.
The demand for spectroscopy technology is increasing due to the rising number of diabetes cases and related complications. This growth is expected as non-invasive procedures, which provide painless and quick monitoring solutions, become more popular. The evolution of cost-effective options will further boost market expansion during the forecast period.
The demand for painless, needle-free, and continuous glucose monitoring wearable sensors is a major factor driving this segment. AerBetic producers a non-invasive blood glucose monitoring that continuously provides blood sugar levels. It also comes with an application that allows a user to set up alerts in order to communicate to a network of health care providers. For instance, in June 2024, Abbott announced U.S. Food and Drug Administration (FDA) clearance for two new over-the-counter continuous glucose monitoring (CGM) systems – Lingo™ and Libre Rio™, which are based on Abbotts world-leading FreeStyle Libre® continuous glucose monitoring technology, now used by about 6 million people globally. The newly cleared systems have been intentionally designed to meet different needs – Lingo for consumers who want to better understand and improve their health and wellness, and Libre Rio for adults with Type 2 diabetes who do not use insulin and typically manage their diabetes through lifestyle modifications.
In 2024, the North America captured 53.20% of the revenue share.
North America Non-Invasive Blood Glucose Monitoring Systems market is driven by high prevalence of diseases and well-established health care infrastructure that enables proper diagnosis are attributed to the North America largest share. According to the American Diabetes Association, in 2018, 34.2 million people in the U.S., or 10.5% of the population, had diabetes. Moreover, 1.6 million people have type 1 diabetes, including about 187,000 children and adolescents.
The US held the largest market share and is anticipated to register the highest CAGR during the forecast period. The market is driven by rising prevalence of diabetes and increasing demand for painless monitoring solutions. The growing number of diabetes cases is pushing consumers to seek alternatives to traditional finger-prick methods, as non-invasive devices provide a pain-free option that enhances compliance.
In Europe, Non-Invasive Blood Glucose Monitoring Systems market is experiencing notable growth, driven by include significant technological advancements, with innovations in sensor technologies such as near-infrared spectroscopy and bioimpedance analysis, enabling accurate and painless glucose monitoring. With both established medical device manufacturers and innovative startups competing in this space, the market is expected to expand significantly as these devices become more accessible and affordable for patients across Europe.
Track market trends LIVE & outsmart rivals with our Premium Data Intel Tool: Vantage Point
Rising Prevalence of Diabetes
The growing prevalence of diabetes among populations in both developed and emerging countries is leading to a large patient pool globally requiring blood monitoring, which is further resulting in increasing demand for these devices among the patient population. Market driven by including rapid urbanization and the rising shift toward a sedentary lifestyle, in emerging and developed countries are primarily responsible for the growing prevalence of diabetes. A significant increase has been observed in the number of patients suffering from type-1 or insulin-dependent type 2 diabetes, which has been instrumental in surging the uptake of blood glucose monitoring systems globally.
High Cost Associated with CGM Systems
The initial purchase price of CGM devices can be substantial, ranging from several hundred to over a thousand dollars, and sensors, which typically need replacement every 7 to 14 days, add significant ongoing expenses. Insurance coverage for CGM systems varies widely, with some plans providing limited coverage or imposing strict approval criteria, leaving patients to shoulder the financial burden. Additionally, proper use of CGM systems often requires training for both patients and healthcare providers, leading to extra costs for consultations and follow-up appointments.
The Non-Invasive Blood Glucose Monitoring Systems market is characterized by dynamic and evolving environment with several key players and their ongoing advancement. Major Players are Abbott Laboratories, Medtronic plc, Dexcom Inc, Ascensia Diabetes Care, Sanofi Novo Nordisk, Insulet corporation, Glysens Incorporated, F.hoffman-La Roche Ltd., Taiwan Biophotonic Corporation. Companies are also forming strategic partnerships with healthcare providers and technology firms to enhance their offerings and navigate regulatory approvals. With the global rise in diabetes cases, companies are expanding geographically to capture new markets, especially by securing key regulatory approvals.
Abbott Enters Global Partnership to Connect Its World-Leading Continuous Glucose Monitoring System with Medtronics Insulin Delivery Devices
The global Non-Invasive Blood Glucose Monitoring Systems market can be categorized as Technology, End User, Modality, Distribution Channel and Region.
Parameter | Details |
---|---|
Segment Covered | By Technology
By End Users
By Modality
By Distribution Channel
By Region
|
Companies Covered |
|
Customization Scope | Enjoy complimentary report customization—equivalent to up to 8 analyst working days—with your purchase. Customizations may include additions or modifications to country, regional, or segment-level data. |
Pricing and purchase options | Access flexible purchase options tailored to your specific research requirements. Explore purchase options |
Key features include:
Contact
Toll Free Number+1 (877) 462-2282